Co-dergocrine plasma concentrations and blood pressure changes in hypertensive patients during therapy with slow-release co-dergocrine mesylate.
In a placebo controlled trial in 20 patients (mean age 38 years) with mild/moderate essential hypertension 4.5 mg slow-release co-dergocrine mesylate was administered once daily for 6 weeks and antihypertensive effects and plasma co-dergocrine concentrations determined 9 hours post-dose. Mean plasma co-dergocrine concentrations were 299 pg/ml, 357 pg/ml and 331 pg/ml measured after 2-, 4-, and 6-weeks administration respectively. Despite these relatively low concentrations there were statistically significant reductions in supine (-6/-6 mmHg), standing (-9/-8 mmHg) and exercise (-8/-5 mmHg) systolic and diastolic blood pressure. Blood glucose fell progressively and was 10% lower (p less than 0.02) after 6 weeks medication. Clinical and laboratory parameters showed that slow-release co-dergocrine mesylate was well tolerated with negligible adverse reactions.
Woodcock
B G
BG
Department of Clinical Pharmacology, University Clinic Frankfurt, Germany.
Herrmann
W
W
Habedank
W D
WD
D000293:Adolescent; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D003692:Delayed-Action Preparations; D004088:Dihydroergotoxine / Q000097:blood*; D004877:Ergoloid Mesylates / Q000378:metabolism / Q000627:therapeutic use*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011863:Radioimmunoassay
D003692:Delayed-Action Preparations; D004088:Dihydroergotoxine; D004877:Ergoloid Mesylates